Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Sep 2019 to Sep 2024
At Pittcon 2006, Bruker AXS Inc. today launches its new
S8 TIGER(TM) X-ray spectrometer for high-performance elemental
analysis in various industrial applications, including petrochemistry,
cement and mining. The S8 TIGER wavelength dispersive X-ray
fluorescence (WDXRF) spectrometer is an innovative high-end system
with numerous new and unique advantages, complementing Bruker AXS'
well established S4 and S2 lines of XRF systems. The S8 TIGER analyzes
all elements from Beryllium to Uranium in a wide variety of sample
types. It is designed for demanding applications in industrial process
and quality control, and as a powerful elemental analysis tool in
research and development departments.
Unique features of the S8 TIGER include TouchControl(TM) and
SampleCare(TM), combining extreme ease of use and robust reliability
with cutting-edge analytical performance. TouchControl responds to
customer requests for facile and fail-safe operation. By using an
integrated touch screen and dedicated user interface, TouchControl
defines a new standard in ease of use for a high-end XRF system. This
enables our industrial customers to deploy the S8 TIGER in a manner
where untrained users can operate the instrument after receiving only
brief instructions. The unique SampleCare feature automatically
recognizes liquid samples and its integrated protection seal protects
the S8 TIGER against all kinds of contamination, ensuring maximum
uptime and availability.
The outstanding analytical performance of the S8 TIGER results
from the innovative optimized X-ray optics. While the new
high-intensity X-ray tube excites the sample even more efficiently,
novel analyzer crystals have been developed for different elements and
specific applications in order to improve detection limits, precision
and resolution.
Dr. Heiko Ress, XRF Marketing Manager for Bruker AXS, comments:
"With the new intuitive TouchControl operation of our S8 TIGER, the
required training for occasional and inexperienced users is absolutely
minimized. Its combination with our new SampleCare protection leads to
unrivalled fail-safe operation, and provides our industrial customers
with a faster return on their investment. In good Bruker AXS
tradition, all these innovative ease of use and uptime features, plus
the high analytical performance come in a very compact, attractive
industrial design. The new S8 TIGER is clearly in a class of its own."
Pittcon 2006, the 57th Pittsburgh Conference and Exposition on
Analytical Chemistry and Applied Spectroscopy, is being held from
March 13-16 in Orlando, Florida in the Orange County Convention
Center. The product introduced here will be exhibited at the Bruker
AXS booth #3155.
ABOUT BRUKER BIOSCIENCES (NASDAQ: BRKR)
Bruker BioSciences Corporation, headquartered in Billerica,
Massachusetts, is the publicly traded parent company of Bruker
Daltonics Inc. and Bruker AXS Inc. Bruker AXS is a leading developer
and provider of life science, materials research and industrial X-ray
analysis tools. Bruker Daltonics is a leading developer and provider
of innovative life science tools based on mass spectrometry. Bruker
Daltonics also offers a broad line of nuclear, biological and chemical
(NBC) detection products for defense and homeland security. For more
information, please visit www.bruker-biosciences.com.
CAUTIONARY STATEMENT
Any statements contained in this press release that do not
describe historical facts may constitute forward-looking statements as
that term is defined in the Private Securities Litigation Reform Act
of 1995. Any forward-looking statements contained herein are based on
current expectations, but are subject to a number of risks and
uncertainties. The factors that could cause actual future results to
differ materially from current expectations include, but are not
limited to, risks and uncertainties relating to the Company's
reorganization strategies, integration risks, failure of conditions,
technological approaches, product development, market acceptance, cost
and pricing of the Company's products, exposure to currency
fluctuations, changes in governmental regulations, capital spending
and government funding policies, FDA and other regulatory approvals to
the extent applicable, competition, the intellectual property of
others, patent protection and litigation. These and other factors are
identified and described in more detail in our filings with the SEC,
including, without limitation, our respective annual reports on Form
10-K, our most recent quarterly reports on Form 10-Q, and our current
reports on Form 8-K. We disclaim any intent or obligation to update
these forward-looking statements.